Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 06 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Buried Barrett's metaplasia eradicated after radiofrequency ablation

This month's issue of Endoscopy examines the prevalence of buried Barrett's metaplasia before and after radiofrequency ablation.

News image

Radiofrequency ablation to treat Barrett's esophagus is increasingly accepted.

Description of the etiology, natural history, and prevalence of buried Barrett's metaplasia following radiofrequency ablation is limited, although buried Barrett's metaplasia continues to pose a clinical dilemma.

Dr Yuan and colleagues assessed the prevalence, characteristics, and eradication rate of Barrett's metaplasia in patients with both dysplastic and nondysplastic Barrett's esophagus, treated with radiofrequency ablation and followed over time.

The presence of Barrett's esophagus, dysplasia, and buried Barrett's metaplasia, before and after radiofrequency ablation, was assessed by 2 gastrointestinal pathologists in a retrospective chart review of patients who had undergone radiofrequency ablation, and had completed appropriate follow-up.

The researchers identified 112 patients with completed treatment, and no further planned radiofrequency ablation.

Buried Barrett's metplasia was found in 71% during the radiofrequency ablation treatment
Endoscopy

In 108, no residual Barrett's esophagus was seen after radiofrequency ablation, and 4 patients with persistent Barrett's tissue underwent surgery.

Regarding Barrett's metaplasia, 15% of patients had evidence of buried Barrett's metaplasia during evaluation.

The team found buried Barrett's metplasia in 71% of patients during the radiofrequency ablation treatment.

The research team found that 8 patients had previously undergone non-radiofrequency ablation therapy and radiofrequency ablation for Barrett's esophagus, and 4 having no previous intervention.

In 29%, Barrett's metaplasia was seen only after radiofrequency ablation monotherapy.

The researchers observed that all 17 showed no evidence of buried Barrett's metaplasia at final evaluation, and were classified in the complete remission group.

Dr Yuan's team concluded, "Both Barrett's esophagus and buried Barrett's metaplasia were completely eradicated in all patients with long-term follow-up after radiofrequency ablation."

"Almost half of the patients with buried Barrett's metaplasia had a prior history of non-radiofrequency ablation therapy for Barrett's esophagus compared with 26% the non-Barrett's metaplasia cohort."

"All patients with previously identified Barrett's esophagus, and buried Barrett's metaplasia were completely cleared of disease at final follow-up."

Endoscopy 2012: 44(11): 993-997
23 November 2012

Go to top of page Email this page Email this page to a colleague

 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 05 December 2016 
Reducing hospitalization in IBD
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Treating Zenker's diverticulum
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 23 November 2016 
Quality assurance standards for colonoscopy
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 21 November 2016 
Financial incentives and colorectal cancer screening
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 17 November 2016 
Liver-related specialty care in patients with Hep C
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Physician perspectives on Hep C management
 15 November 2016 
Contraceptives and ulcerative colitis
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression
 10 November 2016 
Testosterone levels and cirrhosis outcomes in men
 10 November 2016 
Improving bowel quality before colonoscopy
 10 November 2016 
Fecal microbiota transplantation and CDI episodes
 09 November 2016 
Minimizing costs of esophagogastroduodenoscopy and colonoscopy
 09 November 2016 
Risk of TB in IBD patients receiving therapy
 09 November 2016 
Liver transplant wait-list and mortality in infants

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us